10-K Filing

BNB PLUS CORP. CIK: 744452 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001104659-20-136828`
Period End Date	20200930
Filing Date	20201217
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	apdn-20200930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 75 Income Statement 41 Cash Flow Statement 79 Stockholders Equity 22

Balance Sheet 75 line items

Line Item	Tag	Value	Unit	Period
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$4.50K	USD	Point-in-time
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$11.97K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.79M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Accounts receivable, net of allowance of $11,968 and $4,500 at September 30, 2020 and 2019, respectively	`AccountsReceivableNetCurrent`	$839.95K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable, net of allowance of $11,968 and $4,500 at September 30, 2020 and 2019, respectively	`AccountsReceivableNetCurrent`	$194.32K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$142.63K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$497.37K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$599.30K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$604.74K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.15M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$9.08M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$226.22K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.28M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	1.21M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.14M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.14M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	1.21M	shares	Point-in-time
Deferred offering costs	`DeferredCosts`	$109.70K	USD	Point-in-time
Deferred offering costs	`DeferredCosts`	-	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$95.08K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$62.35K	USD	Point-in-time
Goodwill	`Goodwill`	$285.39K	USD	Point-in-time
Goodwill	`Goodwill`	$285.39K	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$605.33K	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$734.77K	USD	Point-in-time
Total Assets	`Assets`	$3.56M	USD	Point-in-time
Total Assets	`Assets`	$11.34M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.62M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.93M	USD	Point-in-time
Promissory notes payable-current portion	`NotesPayableToBankCurrent`	$329.30K	USD	Point-in-time
Secured convertible notes payable , net of debt issuance costs	`ConvertibleNotesPayableCurrent`	$1.50M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$511.04K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$628.99K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.27M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.25M	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$621.97K	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$848.31K	USD	Point-in-time
Promissory notes payable-long term portion	`NotesPayableToBankNoncurrent`	$517.49K	USD	Point-in-time
Secured convertible notes payable, net of debt issuance costs	`ConvertibleLongTermNotesPayable`	$1.44M	USD	Point-in-time
Secured convertible notes payable, recorded at fair value	`SecuredConvertibleNotesPayableNoncurrentFairValueDisclosures`	$102.78K	USD	Point-in-time
Total liabilities	`Liabilities`	$5.63M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.41M	USD	Point-in-time
Commitments and contingencies (Note K)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note K)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2020 and 2019, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2020 and 2019, respectively	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 and 500,000,000 shares authorized as of September 30, 2020 and 2019, respectively; 5,142,779 and 1,207,993 shares issued and outstanding as of September 30, 2020 and 2019, respectively	`CommonStockValue`	$5.14K	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 and 500,000,000 shares authorized as of September 30, 2020 and 2019, respectively; 5,142,779 and 1,207,993 shares issued and outstanding as of September 30, 2020 and 2019, respectively	`CommonStockValue`	$1.21K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$275.55M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$255.96M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-256.81M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-269.84M	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity (deficit):	`StockholdersEquity`	$-841.46K	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity (deficit):	`StockholdersEquity`	$5.72M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-8.72K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-7.04K	USD	Point-in-time
Total equity (deficit)	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Total equity (deficit)	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Total equity (deficit)	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$754.50K	USD	Point-in-time
Total liabilities and equity (deficit)	`LiabilitiesAndStockholdersEquity`	$11.34M	USD	Point-in-time
Total liabilities and equity (deficit)	`LiabilitiesAndStockholdersEquity`	$3.56M	USD	Point-in-time

Income Statement 41 line items

Line Item	Tag	Value	Unit	Period
Interest (expense) income, related party interest	`InterestIncomeRelatedParty`	$46.59K	USD	Annual
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$1.93M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$5.39M	USD	Annual
Cost of revenues	`CostOfRevenue`	$877.61K	USD	Annual
Cost of revenues	`CostOfRevenue`	$720.90K	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.14M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.28M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.32M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.97M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$285.73K	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$390.42K	USD	Annual
Total operating expenses	`OperatingExpenses`	$13.64M	USD	Annual
Total operating expenses	`OperatingExpenses`	$13.75M	USD	Annual
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-12.53M	USD	Annual
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-9.12M	USD	Annual
Interest expense (including related party interest of $46,586 for the year ended September 30, 2019)	`InterestIncomeExpenseNet`	$-162.43K	USD	Annual
Interest expense (including related party interest of $46,586 for the year ended September 30, 2019)	`InterestIncomeExpenseNet`	$-115.83K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-43.30K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-378.07K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-1.26M	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Unrealized gain on change in fair value of secured convertible notes payable	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	-	USD	Annual
Unrealized gain on change in fair value of secured convertible notes payable	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	$1.97M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-13.03M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-8.62M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$15.00K	USD	Annual
NET LOSS	`ProfitLoss`	$-8.63M	USD	Annual
NET LOSS	`ProfitLoss`	$-13.03M	USD	Annual
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.69K	USD	Annual
Less: Net loss (income) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-9.32K	USD	Annual
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-13.03M	USD	Annual
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-8.62M	USD	Annual
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	$-309.61K	USD	Annual
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	$2.84K	USD	Annual
NET LOSS applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-8.93M	USD	Annual
NET LOSS applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-13.03M	USD	Annual
Net loss per share applicable to common stockholders-basic and diluted	`EarningsPerShareBasicAndDiluted`	$-3.32	USD	Annual
Net loss per share applicable to common stockholders-basic and diluted	`EarningsPerShareBasicAndDiluted`	$-9.69	USD	Annual
Weighted average shares outstanding-basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	3.92M	shares	Annual
Weighted average shares outstanding-basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	921,809.00	shares	Annual

Cash Flow Statement 79 line items

Line Item	Tag	Value	Unit	Period
Proceeds from senior convertible notes payable, related party	`ProceedsFromRelatedPartyDebt`	$550.00K	USD	Annual
Net loss	`ProfitLoss`	$-8.63M	USD	Annual
Net loss	`ProfitLoss`	$-13.03M	USD	Annual
Interest paid in kind, related party	`PaidInKindInterestRelatedParty`	$98.75K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$285.73K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$390.42K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-1.26M	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Unrealized gain on change in fair value of senior secured convertible notes	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	-	USD	Annual
Unrealized gain on change in fair value of senior secured convertible notes	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	$1.97M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$1.13M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$1.00M	USD	Annual
Non-cash in process research and development	`ResearchAndDevelopmentInProcess`	$251.42K	USD	Annual
Non-cash in process research and development	`ResearchAndDevelopmentInProcess`	-	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$23.83K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$26.02K	USD	Annual
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$45.28K	USD	Annual
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$7.62K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-638.34K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-600.35K	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$-78.74K	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$354.74K	USD	Annual
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-23.77K	USD	Annual
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$27.29K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$427.37K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$667.90K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$-727.92K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$-117.96K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-11.14M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.86M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.06M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$67.44K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.06M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-67.44K	USD	Annual
Proceeds from secured convertible notes payable (including related parties of $550,000 for the year ended September 30, 2019)	`ProceedsFromIssuanceOfSeniorLongTermDebt`	$1.99M	USD	Annual
Proceeds from secured convertible notes payable (including related parties of $550,000 for the year ended September 30, 2019)	`ProceedsFromIssuanceOfSeniorLongTermDebt`	-	USD	Annual
Proceeds from Promissory notes	`ProceedsFromNotesPayable`	$846.79K	USD	Annual
Proceeds from Promissory notes	`ProceedsFromNotesPayable`	-	USD	Annual
Net proceeds from private placement	`ProceedsFromIssuanceOfPrivatePlacement`	$402.38K	USD	Annual
Net proceeds from private placement	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	Annual
Net proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$987.50K	USD	Annual
Net proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$8.06M	USD	Annual
Net proceeds from sale of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	$2.46M	USD	Annual
Net proceeds from sale of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	$10.64M	USD	Annual
Repayment of convertible notes	`ProceedsFromSecuredConvertibleNotesPayable`	$-107.80K	USD	Annual
Repayment of convertible notes	`ProceedsFromSecuredConvertibleNotesPayable`	$-107.80K	USD	Point-in-time
Repayment of convertible notes	`ProceedsFromSecuredConvertibleNotesPayable`	-	USD	Annual
Capitalized offering costs	`CapitalizedOfferingCostsClassifiedAsFinancingActivities`	$-10.23K	USD	Annual
Capitalized offering costs	`CapitalizedOfferingCostsClassifiedAsFinancingActivities`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.83M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$19.43M	USD	Annual
Net increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.10M	USD	Annual
Net increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$7.23M	USD	Annual
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.66M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.79M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$558.99K	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.66M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.79M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$558.99K	USD	Point-in-time
Cash paid during period for interest	`InterestPaidNet`	$45.35K	USD	Annual
Cash paid during period for interest	`InterestPaidNet`	-	USD	Annual
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	Annual
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	Annual
Public offering costs included in accounts payable and accrued liabilities	`OfferingCostsIncurredAndIncludedInAccountsPayable`	$99.47K	USD	Annual
Public offering costs included in accounts payable and accrued liabilities	`OfferingCostsIncurredAndIncludedInAccountsPayable`	-	USD	Annual
Interest paid in kind (related party of $98,752 for the year ended September 30, 2019)	`PaidInKindInterest`	$35.62K	USD	Annual
Interest paid in kind (related party of $98,752 for the year ended September 30, 2019)	`PaidInKindInterest`	$126.98K	USD	Annual
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	$144.03K	USD	Annual
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	-	USD	Annual
Deemed dividend-warrant repricing	`DeemedDividendWarrantRepricing`	$309.61K	USD	Annual
Deemed dividend-warrant repricing	`DeemedDividendWarrantRepricing`	$2.84K	USD	Annual
Impact of adoption of new accounting pronouncements included in accumulated deficit	`ImpactOfAdoptionOfNewAccountingPronouncementsIncludedInAccumulatedDeficitNonCashFinancingActivities`	-	USD	Annual
Impact of adoption of new accounting pronouncements included in accumulated deficit	`ImpactOfAdoptionOfNewAccountingPronouncementsIncludedInAccumulatedDeficitNonCashFinancingActivities`	$493.22K	USD	Annual
Deferred offering costs reclassified to additional paid in capital	`ReclassificationOfDeferredOfferingCostToAdditionalPaidInCapital`	-	USD	Annual
Deferred offering costs reclassified to additional paid in capital	`ReclassificationOfDeferredOfferingCostToAdditionalPaidInCapital`	$109.70K	USD	Annual
Warrants exercised cashlessly	`WarrantsExercisedCashlessly`	-	USD	Annual
Warrants exercised cashlessly	`WarrantsExercisedCashlessly`	$100.00	USD	Annual
Conversion of notes payable	`ConversionOfStockAmountConverted1`	$1.44M	USD	Annual
Conversion of notes payable	`ConversionOfStockAmountConverted1`	-	USD	Annual

Stockholders Equity 22 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$754.50K	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	5.14M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	1.21M	shares	Point-in-time
Common stock issued in public offering, net of offering costs	`SharesIssuedInPublicOffering`	$-2.46M	USD	Annual
Common stock issued in public offering, net of offering costs	`SharesIssuedInPublicOffering`	$10.53M	USD	Annual
Common stock issued in private placement, net of offering costs	`SharesIssuedInUnderwrittenPrivatePlacement`	$402.38K	USD	Annual
Exercise of warrants	`StockIssuedDuringPeriodValueWarrantsExercised`	$-987.50K	USD	Annual
Exercise of warrants	`StockIssuedDuringPeriodValueWarrantsExercised`	$-8.06M	USD	Annual
Common stock issued in secured convertible note conversion	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$1.44M	USD	Annual
Investment in LineaRx, Inc.	`AdjustmentsToAdditionalPaidInCapitalInvestmentInSubsidiaries`	$113.13K	USD	Annual
Impact of adoption of new accounting pronouncements included in accumulated deficit	`ImpactOfAdoptionOfNewAccountingPronouncementsIncludedInAccumulatedDeficit`	$-493.22K	USD	Annual
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.00M	USD	Annual
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.13M	USD	Annual
Net loss	`ProfitLoss`	$-8.63M	USD	Annual
Net loss	`ProfitLoss`	$-13.03M	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$754.50K	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	5.14M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	1.21M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.